MEDI-573 + sorafenib

MEDI-573 + sorafenib is a **combination regimen** under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC). MEDI-573 is a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody that simultaneously neutralizes both insulin-like growth factor I (IGF-I) and insulin-like growth factor II (IGF-II) ligands, thereby inhibiting their interaction with the insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor. Sorafenib is a small molecule multikinase inhibitor that targets serine/threonine and tyrosine kinases including RAF kinases (CRAF, BRAF), vascular endothelial growth factor receptors (VEGFR-2, VEGFR-3), and platelet-derived growth factor receptor beta (PDGFR-β), exerting antitumor and anti-angiogenic effects. The combination is administered as intravenous MEDI-573 every 21 days with continuous oral sorafenib. The drug was developed primarily for HCC that is unresectable or metastatic, and is being studied for safety and efficacy in phase 1 and 2 clinical trials[2][4][5][7].

Brand names

Nexavar